Accéder au contenu
Merck

Oxaloacetate: a novel neuroprotective for acute ischemic stroke.

The international journal of biochemistry & cell biology (2011-11-17)
Francisco Campos, Tomás Sobrino, Pedro Ramos-Cabrer, José Castillo
RÉSUMÉ

It is well established that glutamate acts as an important mediator of neuronal degeneration during cerebral ischemia. Different kind of glutamate antagonists have been used to reduce the deleterious effects of glutamate. However, their preclinical success failed to translate into practical treatments. Far from the classical use of glutamate antagonists employed so far, the systemic administration of oxaloacetate represents a novel neuroprotective strategy to minimize the deleterious effect of glutamate in the brain tissue after ischemic stroke. The neuroprotective effect of oxaloacetate is based on the capacity of this molecule to reduce the brain and blood glutamate levels as a result of the activation of the blood-resident enzyme glutamate-oxaloacetate transaminase. Here we review the recent experimental and clinical results where it is demonstrated the potential applicability of oxaloacetate as a novel and powerful neuroprotective treatment against ischemic stroke.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Oxaloacetic acid, ≥97% (HPLC)
Sigma-Aldrich
Oxaloacetic acid, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥97% (HPLC)
Sigma-Aldrich
Oxaloacetic acid, powder, suitable for hybridoma